

References

This is the reference list to the ACE Clinical Guidance "Type 2 diabetes mellitus – personalising management with non-insulin medications".

1. International Diabetes Federation. IDF Diabetes Atlas 10th Edition. 2021. Available from: <https://diabetesatlas.org/> [Accessed 21 December 2022].
2. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396(10258):1204-22.
3. Institute for Health Metrics and Evaluation. Singapore 2019. 2019. Available from: www.healthdata.org/singapore [Accessed 21 December 2022].
4. Epidemiology & Disease Control Division and Policy Research & Surveillance Group. National Population Health Survey 2020 (Household Interview and Health Examination). Singapore: Ministry of Health and Health Promotion Board; 2020.
5. World Health Organization. Diabetes. 2022. Available from: <https://www.who.int/news-room/fact-sheets/detail/diabetes> [Accessed 23 Dec 2022].
6. EISayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Care in Diabetes—2023. *Diabetes Care*. 2022;46(Supplement_1):S49-S67.
7. Best Practice Advocacy Centre New Zealand (bpacnz). Type 2 diabetes management toolbox: from lifestyle to insulin. 2021. Available from: <https://bpac.org.nz/2021/diabetes-management.aspx> [Accessed 28 December 2022].
8. EISayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 6. Glycemic targets: Standards of Care in Diabetes—2023. *Diabetes Care*. 2022;46(Supplement_1):S97-S110.
9. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet*. 2010;375(9733):2215-22.
10. EISayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 10. Cardiovascular disease and risk management: Standards of Care in Diabetes—2023. *Diabetes Care*. 2022;46(Supplement_1):S158-S90.
11. Maclsaac RJ, Jerums G, Ekinci EI. Effects of glycaemic management on diabetic kidney disease. *World J Diabetes*. 2017;8(5):172-86.
12. EISayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 11. Chronic kidney disease and risk management: Standards of Care in Diabetes—2023. *Diabetes Care*. 2022;46(Supplement_1):S191-S202.
13. Agency for Care Effectiveness (ACE). Chronic kidney disease - early detection. ACE Clinical Guidance (ACG). 2022. Available from: <https://go.gov.sg/acg-chronic-kidney-disease-early-detection> [Accessed 1 January 2023].
14. EISayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2023. *Diabetes Care*. 2022;46(Supplement_1):S140-S57.
15. National Institute for Health and Care Excellence. Type 2 diabetes in adults: management (NICE guideline NG28). 2022. Available from: <https://www.nice.org.uk/guidance/ng28> [Accessed 1 December 2022].

16. Living Evidence for Diabetes Consortium. Australian evidence-based clinical guidelines for diabetes. 2020. Available from: <https://diabetessociety.com.au/living-guidelines.asp> [Accessed 21 December 2022].
17. Diabetes Canada Clinical Practice Guidelines Expert Committee. Pharmacologic glycaemic management of type 2 diabetes in adults: 2020 Update. *Can J Diabetes*. 2020;44(7):575-91.
18. Dunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai AS, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America. *Circulation*. 2019;140(7):e294-e324.
19. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J*. 2020;41(2):255-323.
20. KDIGO Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. *Kidney Int*. 2022;102(5s):S1-S127.
21. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. *Cardiovasc Diabetol*. 2018;17(1):83.
22. Klein S, Sheard NF, Pi-Sunyer X, Daly A, Wylie-Rosett J, Kulkarni K, et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies. A statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. *Am J Clin Nutr*. 2004;80(2):257-63.
23. Ministry of Health Singapore. Diabetes mellitus: MOH Clinical Practice Guidelines 1/2014. Singapore: Ministry of Health Singapore; 2014.
24. Afshinnia F, Wilt TJ, Duval S, Esmaeili A, Ibrahim HN. Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. *Nephrol Dial Transplant*. 2010;25(4):1173-83.
25. Navaneethan SD, Yehnert H, Moustarah F, Schreiber MJ, Schauer PR, Beddhu S. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. *Clin J Am Soc Nephrol*. 2009;4(10):1565-74.
26. Ministry of Health Singapore. HealthHub: Guide to healthy eating for managing diabetes mellitus. 2022. Available from: <https://www.healthhub.sg/live-healthy/838/healthy-eating-for-managing-diabetes> [Accessed 28 December 2022].
27. Ministry of Health Singapore. HealthHub: Let's BEAT diabetes. 2022. Available from: <https://www.healthhub.sg/programmes/87/diabetes-mellitus> [Accessed 28 December 2022].
28. Ministry of Health Singapore. HealthHub: 3 Be's to Beat Diabetes. 2023. Available from: <https://go.gov.sg/diabetes-materials> [Accessed 24 April 2023].
29. Agency for Care Effectiveness (ACE). Initiating basal insulin in type 2 diabetes mellitus. Appropriate Care Guide (ACG). 2022. Available from: <https://go.gov.sg/acg-initiating-basal-insulin-in-type-2-diabetes-mellitus> [Accessed 28 December 2022].
30. Maruthur N, Tseng E, Huffless S, Wilson L, Suarez-Cuervo C, Berger Z, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes. *Ann Intern Med*. 2016;164(11):740-51.
31. Tsapas A, Avgerinos I, Karagiannis T, Malandris K, Manolopoulos A, Andreadis P, et al. Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. *Ann Intern Med*. 2020;173(4):278-86.

32. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34). *Lancet*. 1998;352:854-65.
33. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med*. 2008;359(15):1577-89.
34. DeFronzo RA, Stonehouse AH, Han J, Wintle ME. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. *Diabet Med*. 2010;27(3):309-17.
35. Hemmingsen B, Schroll JB, Wetterslev J, Gluud C, Vaag A, Sonne DP, et al. Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. *CMAJ Open*. 2014;2(3):E162-75.
36. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*. 2022;45(11):2753-86.
37. Cai X, Gao X, Yang W, Han X, Ji L. Efficacy and safety of initial combination therapy in treatment-naïve type 2 diabetes patients: a systematic review and meta-analysis. *Diabetes Ther*. 2018;9(5):1995-2014.
38. Milder TY, Stocker SL, Abdel Shaheed C, McGrath-Cadell L, Samocha-Bonet D, Greenfield JR, et al. Combination therapy with an SGLT2 inhibitor as initial treatment for type 2 diabetes: a systematic review and meta-analysis. *J Clin Med*. 2019;8(1):45.
39. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *Lancet*. 2019;393(10166):31-9.
40. Arnott C, Li Q, Kang A, Neuen BL, Bompoin S, Lam CSP, et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. *J Am Heart Assoc*. 2020;9(3):e014908.
41. Giugliano D, Longo M, Signoriello S, Maiorino MI, Solerte B, Chiodini P, et al. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs. *Cardiovasc Diabetol*. 2022;21(1):42.
42. Ali MU, Mancini GBJ, Fitzpatrick-Lewis D, Lewis R, Jovkovic M, Zieroth S, et al. The effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists on cardiorenal outcomes: systematic review and meta-analysis. *Can J Cardiol*. 2022;38(8):1201-10.
43. Marsico F, Paolillo S, Gargiulo P, Bruzzese D, Dell'Aversana S, Esposito I, et al. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials. *Eur Heart J*. 2020;41(35):3346-58.
44. Giugliano D, Scappaticcio L, Longo M, Caruso P, Maiorino MI, Bellastella G, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. *Cardiovasc Diabetol*. 2021;20(1):189.
45. Lin DS-H, Lee J-K, Hung C-S, Chen W-J. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials. *Diabetologia*. 2021;64(12):2676-86.

46. Li X, Song Y, Guo T, Xiao G, Li Q. Effect of glucagon-like peptide 1 receptor agonists on the renal protection in patients with type 2 diabetes: a systematic review and meta-analysis. *Diabetes Metab.* 2022;48(5):101366.
47. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. *Circulation.* 2014;130(18):1579-88.
48. Institute of Medicine (US) Committee on Quality of Health Care in America. *Crossing the Quality Chasm: A New Health System for the 21st Century.* Washington (DC): National Academies Press (US); 2001. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK222271/>.
49. What is patient-centered care? *NEJM Catalyst.* 2017;January 1, 2017.
50. Titchener J. A patient-centred clinical approach to diabetes care assists long-term reduction in HbA1c. *J Prim Health Care.* 2014;6(3):195-202.
51. Tai ES, Yew TW. Person-centred care in diabetes: what is it based on and does it work? *Singapore Fam Physician.* 2020;46(7):11-5.
52. Williams JS, Walker RJ, Smalls BL, Hill R, Egede LE. Patient-centered care, glycemic control, diabetes self-care, and quality of life in adults with type 2 diabetes. *Diabetes Technol Ther.* 2016;18(10):644-9.
53. Lin LK, Sun Y, Heng BH, Chew DEK, Chong PN. Medication adherence and glycemic control among newly diagnosed diabetes patients. *BMJ Open Diabetes Res Care.* 2017;5(1):e000429.
54. Health Services and Outcomes Research NHG. 7 in 20 newly-diagnosed diabetes patients do not adhere to medication. 2017. Available from: <https://corp.nhg.com.sg/Media%20Releases/Medication%20Non-%20Adherence%20in%20Newly-Diagnosed%20Diabetes%20Patients%20is%20associated%20with.pdf> [Accessed 18 January 2023].
55. Lee CS, Tan JHM, Sankari U, Koh YLE, Tan NC. Assessing oral medication adherence among patients with type 2 diabetes mellitus treated with polytherapy in a developed Asian community: a cross-sectional study. *BMJ Open.* 2017;7(9):e016317.
56. Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. *Patient Prefer Adherence.* 2016;10:1299-307.
57. García-Pérez L-E, Álvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D. Adherence to therapies in patients with type 2 diabetes. *Diabetes Ther.* 2013;4(2):175-94.
58. McGill M, Blonde L, Chan JC, Khunti K, Lavalley FJ, Bailey CJ. The interdisciplinary team in type 2 diabetes management: challenges and best practice solutions from real-world scenarios. *J Clin Transl Endocrinol.* 2017;7:21-7.
59. Bain S, Cummings M, McKay G. Multidisciplinary approach to management and care of patients with type 2 diabetes mellitus. *EMJ Diabetes.* 2019;7(1):73-81.
60. Ministry of Health Singapore. *Chronic disease management programme. Handbook for healthcare professionals.* Singapore: Ministry of Health Singapore; 2022.